27734402|t|Analysis of Pathological Activities of CCN2/CTGF in Muscle Dystrophy
27734402|a|CCN2 or connective tissue growth factor (CTGF) is a matricellular protein that regulates several cellular processes. In skeletal muscle, CTGF is a key modulator of fibrogenesis, is increased in pathological conditions such as muscular dystrophies, and plays a major role in the pathology outcome. Overexpression of CTGF in skeletal muscle of wild-type mice results in muscle damage, fibrosis, and reduction of strength. In contrast, a decrease in CTGF in dystrophic mice increases strength and reduces damage and fibrosis. Thus, CTGF is a relevant target to study in skeletal muscle pathology and its possible modulation by different treatments or potential new drugs to develop new strategies for the treatment of muscular dystrophies. We summarize the techniques used to detect CTGF in the skeletal muscle of dystrophic mdx mice.
27734402	0	8	Analysis	T062	C0936012
27734402	12	35	Pathological Activities	T169	C0205469
27734402	39	48	CCN2/CTGF	T116,T123	C0110610
27734402	52	68	Muscle Dystrophy	T047	C0026850
27734402	69	73	CCN2	T116,T123	C0110610
27734402	77	108	connective tissue growth factor	T116,T123	C0110610
27734402	110	114	CTGF	T116,T123	C0110610
27734402	121	142	matricellular protein	T116,T123	C0079323
27734402	166	184	cellular processes	T043	C1325880
27734402	189	204	skeletal muscle	T024	C0242692
27734402	206	210	CTGF	T116,T123	C0110610
27734402	233	245	fibrogenesis	T040	C0596570
27734402	263	286	pathological conditions	T046	C0030660
27734402	295	315	muscular dystrophies	T047	C0026850
27734402	347	364	pathology outcome	T033	C0679250
27734402	366	380	Overexpression	T045	C0017262
27734402	384	388	CTGF	T028	C1413791
27734402	392	407	skeletal muscle	T024	C0242692
27734402	411	425	wild-type mice	T015	C1520150
27734402	437	450	muscle damage	T020	C0410158
27734402	452	460	fibrosis	T046	C0016059
27734402	466	475	reduction	T080	C0392756
27734402	479	487	strength	T081	C0237897
27734402	504	512	decrease	T081	C0547047
27734402	516	520	CTGF	T028	C1413791
27734402	524	534	dystrophic	T169	C0333607
27734402	535	539	mice	T015	C0025929
27734402	540	549	increases	T169	C0442805
27734402	550	558	strength	T081	C0237897
27734402	563	570	reduces	T080	C0392756
27734402	571	577	damage	T169	C1883709
27734402	582	590	fibrosis	T046	C0016059
27734402	598	602	CTGF	T116,T123	C0110610
27734402	608	616	relevant	T080	C2347946
27734402	617	623	target	T169	C1521840
27734402	636	651	skeletal muscle	T024	C0242692
27734402	693	702	different	T080	C1705242
27734402	703	713	treatments	T061	C0087111
27734402	717	726	potential	T080	C3245505
27734402	727	730	new	T080	C0205314
27734402	731	736	drugs	T121	C1254351
27734402	740	747	develop	T169	C1527148
27734402	748	751	new	T080	C0205314
27734402	771	780	treatment	T061	C0087111
27734402	784	804	muscular dystrophies	T047	C0026850
27734402	823	833	techniques	T169	C0449851
27734402	842	848	detect	T033	C0442726
27734402	849	853	CTGF	T116,T123	C0110610
27734402	861	876	skeletal muscle	T024	C0242692
27734402	880	890	dystrophic	T169	C0333607
27734402	891	899	mdx mice	T015	C0206535